BioMedNewsBreaks – HealthLynked Corp. (OTCQB: HLYK) Adds Insurance and Employer-Benefits Leaders Chris Pulos and Jason Bishara to Board

HealthLynked (OTCQB: HLYK), an AI-driven global healthcare network focused on improving care coordination and reducing costs, appointed Chris G. Pulos of Marsh McLennan Agency and Jason Bishara of NSI Insurance Group to its Board. The Company said the additions bring decades of experience in employer benefits, payer strategy, insurance and risk management as HealthLynked expands collaborations with insurers, employer groups and healthcare organizations. Founder and CEO Dr. Michael Dent said their expertise will support national scaling of the HealthLynked Network and its AI platform, ARI, while strengthening governance ahead of a planned Nasdaq Capital Market listing.

To view the full press release, visit https://ibn.fm/o8j6p

About HealthLynked Corp.

HealthLynked Corp. enhances healthcare through personalized care management that improves outcomes and reduces costs. Its cloud-based platform connects patients with providers for virtual or in-office appointments and consolidates medical records into one secure, accessible location.

With AI-driven insights and integrated telehealth services, HealthLynked empowers patients and providers to coordinate care more effectively, while delivering substantial savings on prescriptions and healthcare services. The platform supports enterprise partnerships, offering scalable solutions to healthcare networks and digital health innovators.

NOTE TO INVESTORS: The latest news and updates relating to HLYK are available in the company’s newsroom at https://ibn.fm/HLYLK

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer

VERAXA Biotech (NASDAQ: VRXA) announced the appointment of Christoph Erkel, Ph.D., as chief scientific officer,…

2 days ago

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Publishes Preclinical Data Supporting IV Cancer Therapy

Oncotelic Therapeutics (OTCQB: OTLC) together with Sapu Nano, announced publication of a peer-reviewed study in Biomedicines detailing the preclinical data supporting…

3 days ago

BioMedNewsBreaks — VivoSim Labs, Inc. (NASDAQ: VIVS) Announces $4 Million Private Placement 

VivoSim Labs, Inc. (NASDAQ: VIVS) announced it has entered into a securities purchase agreement with a single…

4 days ago

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Receives Japan Patent Allowance for GelrinC Manufacturing Technology 

Regentis Biomaterials (NYSE American: RGNT) announced that the Japan Patent Office has issued a Notice of Allowance…

5 days ago

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform

VERAXA Biotech (NASDAQ: VRXA) announced it has received Scientific Advice from Germany's Paul-Ehrlich-Institute regarding the…

5 days ago

BioMedNewsBreaks — MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Advances Voice-Based AI Technology for Real-Time Impairment Detection

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio…

1 week ago